Brief: FRACTURE IDE Trial Of The Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter Meets Primary Safety And Effectiveness Endpoints
19/05/2026 11:34
May 19 (Reuters) - Boston Scientific Corp BSX.N: FRACTURE IDE TRIAL OF THE BOSTON SCIENTIFIC SEISMIQ™ 4CE CORONARY INTRAVASCULAR LITHOTRIPSY CATHETER MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS BOSTON SCIENTIFIC CORP - FRACTURE TRIAL REPORTS 93.3% FREEDOM FROM MACE AT 30 DAYS, EXCEEDING PERFORMANCE GOAL Source text: ID:nPn25tZwFa Further company coverage: BSX.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Boston Scientific
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
U.S. RESEARCH ROUNDUP-Autodesk, Dell Technologies, Hyatt Hotels
Live Markets: Eight trillion reasons UBS wants you to bet on longevity
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
U.S. STOCKS ON THE MOVE-Boston Scientific, Banc of California, Salesforce